Top

Arthritis Research & Therapy

Published in:

Open Access 01-12-2015 | Research article

Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS

Authors: Janine Bleil, Joachim Sieper, Rene Maier, Uwe Schlichting, Axel Hempfing, Uta Syrbe, Heiner Appel

Published in: Arthritis Research & Therapy | Issue 1/2015

Abstract

Introduction

In ankylosing spondylitis (AS), joint remodeling leading to joint ankylosis involves cartilage fusion. Here, we analyzed whether chondrocyte hypertrophy is involved in cartilage fusion and subsequent joint remodeling in AS.

Methods

We assessed the expression of chondrocyte hypertrophy markers runt-related transcription factor 2 (Runx2), type X collagen (COL10), matrix metalloproteinase 13 (MMP13), osteocalcin and beta-catenin and the expression of positive bone morphogenic proteins (BMPs) and negative regulators (dickkopf-1 (DKK-1)), sclerostin, (wingless inhibitory factor 1 (wif-1)) of chondrocyte hypertrophy in the cartilage of facet joints from patients with AS or osteoarthritis (OA) and from autopsy controls (CO) by immunohistochemistry. Sex determining region Y (SRY)-box 9 (Sox9) and type II collagen (COL2) expression was assessed as indicators of chondrocyte integrity and function.

Results

The percentage of hypertrophic chondrocytes expressing Runx2, COL10, MMP13, osteocalcin or beta-catenin was significantly increased in OA but not in AS joints compared to CO joints. Frequencies of sclerostin-positive and DKK-1-positive chondrocytes were similar in AS and CO. In contrast, wif-1- but also BMP-2- and BMP-7-expressing and Sox9-expressing chondrocytes were drastically reduced in AS joints compared to CO as well as OA joints whereas the percentage of COL2-expressing chondrocytes was significantly higher in AS joints compared to CO joints.

Conclusions

We found no evidence for chondrocyte hypertrophy within hyaline cartilage of AS joints even in the presence of reduced expression of the wnt inhibitor wif-1 suggesting that chondrocyte hypertrophy is not a predominant pathway involved in joint fusion and remodeling in AS. In contrast, the reduced expression of Sox9, BMP-2 and BMP-7 concomitantly with induced COL2 expression rather point to disturbed cartilage homeostasis promoting cartilage degeneration in AS.

Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–90. doi:10.1016/S0140-6736(07)60635-7.PubMedCrossRef

de Vlam K, Mielants H, Veys EM. Involvement of the zygapophyseal joint in ankylosing spondylitis: relation to the bridging syndesmophyte. J Rheumatol. 1999;26:1738–45.PubMed

Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol. 1983;22:25–8.PubMedCrossRef

Bleil J, Maier R, Hempfing A, Schlichting U, Appel H, Sieper J, et al. Histomorphological and histomorphometric characteristics of zygapophyseal joint remodelling in ankylosing spondylitis. Arthritis Rheumatol. 2014;66:1745–54. doi:10.1002/art.38404.PubMedCrossRef

Francois RJ, Gardner DL, Degrave EJ, Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 2000;43:2011–24. doi:10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y.PubMedCrossRef

Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69:592–7. doi:10.1136/ard.2008.102046.PubMedCrossRef

Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–50. doi:10.1016/j.devcel.2005.03.016.PubMedCrossRef

Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res. 2009;24:12–21. doi:10.1359/jbmr.080901.PubMedCentralPubMedCrossRef

Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem. 2005;95:445–53. doi:10.1002/jcb.20420.PubMedCrossRef

10.

Ueta C, Iwamoto M, Kanatani N, Yoshida C, Liu Y, Enomoto-Iwamoto M, et al. Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J Cell Biol. 2001;153:87–100.PubMedCentralPubMedCrossRef

11.

Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH. Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. Osteoarthritis Cartilage. 2004;12:963–73. doi:10.1016/j.joca.2004.08.008.PubMedCrossRef

12.

Takeda S, Bonnamy JP, Owen MJ, Ducy P, Karsenty G. Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. Genes Dev. 2001;15:467–81. doi:10.1101/gad.845101.PubMedCentralPubMedCrossRef

13.

Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A. 2004;101:17192–7. doi:10.1073/pnas.0407788101.PubMedCentralPubMedCrossRef

14.

Studer D, Millan C, Ozturk E, Maniura-Weber K, Zenobi-Wong M. Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells. Eur Cell Mater. 2012;24:118–35. discussion 35.PubMed

15.

van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev. 2003;24:782–801. doi:10.1210/er.2002-0033.PubMedCrossRef

16.

Shen G. The role of type X collagen in facilitating and regulating endochondral ossification of articular cartilage. Orthod Craniofac Res. 2005;8:11–7. doi:10.1111/j.1601-6343.2004.00308.x.PubMedCrossRef

17.

Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006;54:1736–46. doi:10.1002/art.21897.PubMedCrossRef

18.

Rountree RB, Schoor M, Chen H, Marks ME, Harley V, Mishina Y, et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol. 2004;2:e355. doi:10.1371/journal.pbio.0020355.PubMedCentralPubMedCrossRef

19.

Surmann-Schmitt C, Widmann N, Dietz U, Saeger B, Eitzinger N, Nakamura Y, et al. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci. 2009;122:3627–37. doi:10.1242/jcs.048926.PubMedCrossRef

20.

Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003;423:332–6. doi:10.1038/nature01657.PubMedCrossRef

21.

Martel-Pelletier J, Boileau C, Pelletier JP, Roughley PJ. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008;22:351–84. doi:10.1016/j.berh.2008.02.001.PubMedCrossRef

22.

Umlauf D, Frank S, Pap T, Bertrand J. Cartilage biology, pathology, and repair. Cell Mol Life Sci. 2010;67:4197–211. doi:10.1007/s00018-010-0498-0.PubMedCrossRef

23.

Schroeppel JP, Crist JD, Anderson HC, Wang J. Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol Histopathol. 2011;26:377–94.PubMed

24.

Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone. 2012;51:204–11. doi:10.1016/j.bone.2011.10.010.PubMedCrossRef

25.

van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage. 2007;15:237–44. doi:10.1016/j.joca.2006.11.006.PubMedCrossRef

26.

Hennig T, Lorenz H, Thiel A, Goetzke K, Dickhut A, Geiger F, et al. Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J Cell Physiol. 2007;211:682–91. doi:10.1002/jcp.20977.PubMedCrossRef

27.

Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol. 2005;32:876–86.PubMed

28.

Drissi H, Zuscik M, Rosier R, O’Keefe R. Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis. Mol Aspects Med. 2005;26:169–79. doi:10.1016/j.mam.2005.01.003.PubMedCrossRef

29.

Madry H, Luyten FP, Facchini A. Biological aspects of early osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2012;20:407–22. doi:10.1007/s00167-011-1705-8.PubMedCrossRef

30.

Flemming A. Target identification: HIF2alpha central player in osteoarthritis. Nat Rev Drug Discov. 2010;9:517. doi:10.1038/nrd3210.PubMedCrossRef

31.

Pitsillides AA, Beier F. Cartilage biology in osteoarthritis–lessons from developmental biology. Nat Rev Rheumatol. 2011;7:654–63. doi:10.1038/nrrheum.2011.129.PubMedCrossRef

32.

Ma B, Leijten JC, Wu L, Kip M, van Blitterswijk CA, Post JN, et al. Gene expression profiling of dedifferentiated human articular chondrocytes in monolayer culture. Osteoarthritis Cartilage. 2013;21:599–603. doi:10.1016/j.joca.2013.01.014.PubMedCrossRef

33.

Stock M, Bohm C, Scholtysek C, Englbrecht M, Furnrohr BG, Klinger P, et al. Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor alpha-mediated experimental arthritis. Arthritis Rheum. 2013;65:2310–22. doi:10.1002/art.38054.PubMedCrossRef

34.

Markway BD, Cho H, Johnstone B. Hypoxia promotes redifferentiation and suppresses markers of hypertrophy and degeneration in both healthy and osteoarthritic chondrocytes. Arthritis Res Ther. 2013;15:R92. doi:10.1186/ar4272.PubMedCentralPubMedCrossRef

35.

Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 2008;58:2053–64. doi:10.1002/art.23614.PubMedCentralPubMedCrossRef

36.

Cruickshank B. Histopathology of diarthrodial joints in ankylosing spondylitis. Ann Rheum Dis. 1951;10:393–404.PubMedCentralPubMedCrossRef

37.

Cruickshank B. Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol. 1956;71:73–84.PubMedCrossRef

38.

Ball J. Articular pathology of ankylosing spondylitis. Clin Orthop Relat Res. 1979:30–7.

Title: Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS
Authors: Janine Bleil
Joachim Sieper
Rene Maier
Uwe Schlichting
Axel Hempfing
Uta Syrbe
Heiner Appel
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2015
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-015-0675-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

68Ga-DOTA-Siglec-9 – a new imaging tool to detect synovitis

Tumor necrosis factor-α blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study

Direct effects of HP Acthar Gel® on human B lymphocyte activation in vitro

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab

Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis

Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials